The US Food and Drug Administration granted approval for Izervay to treat GA secondary to AMD. Credit: Jo Panuwat D / Shutterstock.com.

Astellas Pharma has reported data from the Phase III GATHER2 clinical trial where Izervay [avacincaptad pegol (ACP) intravitreal solution] reduced geographic atrophy (GA) lesion growth rate in individuals with GA secondary to age-related macular degeneration (AMD). 

The double-masked, randomised, multicentre, sham-controlled trial is designed to assess the efficacy and safety of Izervay in 448 subjects. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

For 12 months, subjects received a monthly dose of ACP or sham. In the second year, they were given ACP every month (EM) or every other month (EOM).

Through two years, the EM dosing schedule of Izervay offered a statistically significant year-over-year 14% decline in mean GA growth rate from baseline compared to sham, thereby meeting the primary objective.

Izervay when given EOM offered a 19% reduction in the mean GA growth rate versus sham.

See Also:

The treatment was well tolerated for over two years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Conjunctival haemorrhage, higher intraocular pressure and choroidal neovascularisation were observed as the most frequent ocular treatment-emergent adverse events (TEAEs) in the trial.

Astellas company IVERIC bio senior vice-president and chief development officer Dhaval Desai said: “We are pleased with these new results and look forward to sharing the findings with regulatory health authorities. 

“Patients are at the centre of all we do, and Astellas is committed to advancing research and developing transformational therapies for people living with retinal diseases.” 

The US Food and Drug Administration granted approval for Izervay in August this year to treat GA secondary to AMD.